Leonardo Faoro

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

Tanguy Y. Seiwert, Ramasamy Jagadeeswaran, Leonardo Faoro et al. · Cancer Research · 2009 · 265 citations · Full text

Medicine, Oncology, Pharmacology +17

Activating <i>NOTCH1</i> Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

Renata Ferrarotto, Yoshitsugu Mitani, Lixia Diao et al. · Journal of Clinical Oncology · 2017 · 245 citations · Full text

Veterinary Medicine, Molecular Biology, Oncology +17

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Marcia S. Brose, Bruce Robinson, Steven I. Sherman et al. · The Lancet Oncology · 2021 · 243 citations

Medicine, Oncology, Pharmacology +12

Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

David R. Spigel, P. Townley, David Waterhouse et al. · Journal of Clinical Oncology · 2011 · 226 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia

Halla Nimeiri, Amit M. Oza, Robert J. Morgan et al. · Gynecologic Oncology · 2008 · 151 citations · Full text

Medicine, Gynecology, Oncology +11